Connect with us

Marijuana Movement

Utah Chooses Akerna’s Leaf Data System for Cannabis Seed-to-Sale Trackability Purposes

Emma Jay



Utah Chooses Akerna’s Leaf Data System for Cannabis Seed-to-Sale Trackability Purposes

It has been recently revealed by MJ Biz Daily, that the state of Utah has selected Akerna’s Leaf Data Systems with the intentions of tracking medical marijuana supply chains.

Akerna is deemed the parent company of the merging of two companies, MJ Freeway and MTech Acquisition Corp – now known as the first U.S.-listed Special Purpose Acquisition Company (SPAC).

Here’s what the team at Akerna had to say about their endeavors within the cannabis market:

“We believe connected data and information will modernize and propel the cannabis industry increasing the power of businesses, governments, patients and consumers to make smart decisions.”

That said, Akerna’s Leaf Data System originally belonged to MJ Freeway, where the software solution permits the government to measure every spec of the cannabis plant, i.e. from seed-to-sale. This in turn ensures that the products available in the market aren’t only safe, but also the health of patients and the general public.

Utah isn’t the only one to make use of such a notable solution, as the states, Pennsylvania and Washington have also incorporated the Leaf Data System from medical marijuana and recreational cannabis-uses assessments respectively.

Emma Jay is one of the most esteemed suppliers of COR cannabis content who loves to find facts and figures as well as stuff plenty of statistics and tidbits backed by research. Stemming with authenticity as a Certified HIPAA Professional in healthcare, Section 504 Coordinator Certificate in Legal and Certified Housing Asset Manager in Real Estate. Boasting over a decade-long stint in community healthcare, EJ will now be helping carry the COR torch into the future.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *


Join Us On Facebook


Trending CBD News

TimesofCBD always fact checks sources and aims for the best accuracy in the reporting curated cannabis content consisting of the latest CBD news, user guides and product health research. Quality is the priority, but we are not eligible to be liable as everything here is for educational, informational purposes only. Always seek real additional medical advice and consultation with a professional healthcare practitioner before considering any CBD. No statements found on this website have underwent Food and Drug Administration evaluation. The efficacy of any products or claims made have never been approved by the FDA either. No products shall ever be intended to diagnose, treat or cure any disease or prevent any ailment.

What Is CBD?